|

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

RECRUITINGN/ASponsored by University of Rochester
Actively Recruiting
PhaseN/A
SponsorUniversity of Rochester
Started2025-11-17
Est. completion2031-06-30
Eligibility
Age18 Years – 79 Years
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07630402

Summary

The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).

Eligibility

Age: 18 Years – 79 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Female sex, age 18-79 years.
* Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT
* Baseline LVEF ≥ 55 % by 2-D echocardiography.
* Ability to provide informed consent.

Exclusion Criteria:

* Prior HF, myocardial infarction, or cardiomyopathy.
* Atrial fibrillation or significant valvular heart disease.
* Cumulative anthracycline dose ≥ 250 mg/m².
* Pregnancy or lactation.
* Inability to comply with study procedures.

Conditions3

Breast CancerBreast Cancer With Low to Intermediate HER2 ExpressionCancer

Locations1 site

Wilmot Cancer Center
Rochester, New York, 14642
Farhan Bajwa, MD, FACC

Find trials near these locations

All trials in New York

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.